DJIA 18,037.97 -42.17 -0.23%
NASDAQ 5,060.25 -31.84 -0.63%
S&P 500 2,108.92 -8.77 -0.41%
market minute promo

Celgene (NASDAQ: CELG)

114.72 -4.00 (-3.37%)

REAL-TIME: Last trade at

Extended Hours: $114.98 $0.27 (0.23%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

CELG $114.72 -3.37%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $119.20
Previous Close $118.71
Daily Range $114.31 - $119.38
52-Week Range $69.88 - $129.06
Market Cap $91.8B
P/E Ratio 49.67
Dividend (Yield) $0.00 (0.0%)
Volume 6,813,283
Average Daily Volume 5,914,440
Current FY EPS $4.42

Sector

Healthcare

Industry

Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/

News & Commentary Rss Feed

Biotech Bubble Bursting? 3 Stocks I Want to Buy

Celgene Corporation, Amgen Inc., and Gilead Sciences Inc. may be good biotech stocks to buy on a sell-off.

Jim Cramer's 'Mad Money' Recap: Market Squall Making Me Seasick

Nasdaq Backs Off Record High as Biotech Drags Markets Lower

AstraZeneca Falls on Q1 Earnings Decline, Reiterates View - Analyst Blog

The Real Value In MabVax May Be Partnerships Rather Than Pipeline

Biotech And Healthcare Investment: It's Not Your Father's Healthcare Sector Anymore

Short Sellers Become More Wary of Big Biotech

Benzinga's Weekend M&A Chatter

3 Mega-Cap Stocks That Shouldn't Pay a Dividend

Mega-cap stocks are generally profitable and overflowing with free cash, leading many to pay handsome dividends. However, these three mega-cap stocks aren't currently paying a dividend -- and if their management teams are smart, they'll keep it that way for many years to come!

Trusty Horses; Tools, Pizza and Shoes: Jim Cramer's Best Blogs

See More CELG News...

CELG's Top Competitors

CELG $114.72 (-3.37%)
Current stock: CELG
$0.00 (0.00%)
Current stock:
AMGN $162.38 (-3.29%)
Current stock: AMGN
BIIB $389.27 (-3.10%)
Current stock: BIIB